^
Association details:
Biomarker:RUNX1-RUNX1T1 fusion
Cancer:Acute Myelogenous Leukemia
Regimen:DA (cytarabine + daunorubicin)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients

Published date:
12/22/2018
Excerpt:
Patients with RUNX1-RUNX1T1 gene fusion were significantly more likely to achieve complete remission (CR) after DA60 induction therapy (p = 0.026), as were patients without the ASXL1 mutation (p = 0.007).
DOI:
10.1186/s12935-018-0716-7